Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With VVA
Prospective, Open-label, Monocenter, Trial to Investigate the Efficacy and Tolerability of WO533, a Lactic Acid Containing Vaginal Suppository, in a Panel of Post-menopausal Women Suffering From Vulvovaginal Atrophy (VVA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Schenefeld, Germany
- proDERM Institute for Applied Dermatological Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Post-menopausal women with subjective symptomatology of vulvovaginal atrophy
- Signed written informed consent before participation in the trial
Exclusion Criteria:
- Known hypersensitivity against any of the ingredients of the investigational product
- Systemic hormonal replacement therapy, or phytohormonal therapy or use of SERMs within 3 months before and / or during the conduct of the trial
- Local hormonal therapy (vagina/vulva) within 3 months before the trial
- If in the opinion of the investigator the patient should not participate in the study for any reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: WO533
Formulation containing WO533 for intravaginal application
|
Intravaginal application
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
VMI
Time Frame: Day 1 to 43
|
Change of the Vaginal Maturation Index (VMI)
|
Day 1 to 43
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vaginal pH
Time Frame: Day 1 to 8, day 8 to 43, and day 1 to 43
|
Change of vaginal pH
|
Day 1 to 8, day 8 to 43, and day 1 to 43
|
|
Subjective vulvovaginal atrophy symptoms
Time Frame: Day 1 to 8, day 8 to 43, and day 1 to 43
|
Change of severity scoring for each of the subjective symptoms (dryness, itching, burning and pain unrelated to sexual intercourse) and as sum score
|
Day 1 to 8, day 8 to 43, and day 1 to 43
|
|
Global judgment of the tolerability by the Investigator
Time Frame: Day 1 to 43
|
Scoring on a scale from 1 to 4
|
Day 1 to 43
|
|
Global judgment of the tolerability by the patient
Time Frame: Day 1 to 43
|
Scoring on a scale from 1 to 4
|
Day 1 to 43
|
|
Adverse events
Time Frame: Day 1 to 43
|
Day 1 to 43
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Kirstin Deuble-Bente, MD, proDERM Institute for Applied Dermatological Research, Germany
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- VMP-03/2018
- 2019-002325-30 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.